Sarah McFarlane

1 week ago | healtheconomics.com | Sarah McFarlane

In a landmark decision, a federal judge has vacated the National Institutes of Health’s (NIH) decision to cut funding for research projects related to diversity, equity, and inclusion (DEI), LGBTQ+ issues, and gender identity. The American Civil Liberties Union (ACLU) hailed the ruling as a major victory for public health, as the court ordered the reinstatement of research funding that had been terminated under NIH’s directives.

1 week ago | healtheconomics.com | Sarah McFarlane

The biopharma industry faced a setback as the Senate’s version of the One Big Beautiful Bill Act, linked to President Donald Trump’s tax reforms, excluded the Orphan Cures Act, a provision aimed at amending an Inflation Reduction Act (IRA) clause affecting rare disease treatments. This bipartisan act sought to exempt drugs with multiple rare disease indications from Medicare’s price negotiations, an exemption currently applicable only to drugs treating a single rare disease under the IRA.

2 weeks ago | healtheconomics.com | Sarah McFarlane

Ensuring data integrity in clinical trials is crucial, as emphasized by the International Council for Harmonization’s E6 (R3) guidelines. This article delves into the role of statistical data monitoring in identifying potential data manipulation, highlighting the effectiveness of various statistical tests for continuous variables in detecting deliberate data falsification.

2 weeks ago | healtheconomics.com | Sarah McFarlane

At a recent European Parliament event, the European Migraine and Headache Alliance (EMHA) called on EU policymakers to include migraine in the forthcoming Neurological Health Strategy. Despite affecting up to 15% of adults in Europe and being a leading cause of disability among young women, migraine remains underdiagnosed and undertreated.

2 weeks ago | healtheconomics.com | Sarah McFarlane

This episode features Matt McLoughlin, Senior Vice President of Compliance and Categories at Scientist.com. With 25 years in pharma R&D and Procurement, Matt has enhanced outsourcing for biopharma companies, focusing on speed, efficiency, and compliance. His expertise in regulated industries extends to RWE, HEOR, and Market Access, transforming access to external services to boost innovation while cutting costs and project timelines. Watch the interview to learn more!Unable able to watch?